SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Meta Expands AI Training With Employee Activity Tracking Tools 
BERKELEY, Calif., March 02, 2016 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company’s Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Cowen and Company Health Care Conference on Monday, March 7, 2016 at 2:40 p.m. ET.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 30 days following the presentation.
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism. For more information, visit www.xoma.com.
Company and Investor Contact: Ashleigh Barreto 510-204-7482 [email protected] Juliane Snowden The Oratorium Group, LLC [email protected] Media Contact: Ryan Flinn W2O Group 415-946-1059 [email protected]
